MARKET

BHC

BHC

Bausch Health Companies Inc
NYSE
6.52
+0.02
+0.23%
Opening 09:32 05/21 EDT
OPEN
6.51
PREV CLOSE
6.50
HIGH
6.56
LOW
6.49
VOLUME
57.46K
TURNOVER
0
52 WEEK HIGH
11.46
52 WEEK LOW
6.49
MARKET CAP
2.39B
P/E (TTM)
-5.2342
1D
5D
1M
3M
1Y
5Y
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
Bausch Health Companies Inc. (NYSE:BHC) has seen a 25% share price drop in the last month. The company's share price is down 26% in a year and its price-to-sales ratio is lower than the Pharmaceuticals industry. With poor revenue growth, the company's P/S ratio may not be sending strong signals. Baush Health Companies has a low revenue growth rate compared to most other companies in its industry.
Simply Wall St · 2h ago
Weekly Report: what happened at BHC last week (0513-0517)?
Weekly Report · 1d ago
Bausch Health Cos. Inc. Stock Falls Friday, Underperforms Market
Shares of Bausch Health Cos. Inc. Closed below its 52-week high (C$) on Friday. The company slid to C$ in a positive trading session for the Canadian market. The S&P/TSX Composite Index rose to 22. BHC's trading volume of 448,540 shares eclipsed its 50-day average.
MarketWatch · 3d ago
Bausch Health Cos. Inc. Stock Falls Thursday, Underperforms Market
Shares of Bausch Health Cos. Inc. Closed below its 52-week high (C$) on Thursday. The S&P/TSX Composite Index rose to 22 in a positive trading session for the Canadian market. The company's shares of BHC shed to C$ in Thursday's trading session.
MarketWatch · 4d ago
Bausch Health Cos. Inc. Stock Falls Wednesday, Underperforms Market
Shares of Bausch Health Cos. Inc. Closed below its 52-week high (C$) on Wednesday. The company's stock slid to C$. The S&P/TSX Composite Index rose to 22, with the Canadian market in a generally positive trading session.
MarketWatch · 5d ago
Bausch Health Shareholders Approve Key Proposals
TipRanks · 5d ago
Bausch Health Defends XIFAXAN Patents Amid Litigation
TipRanks · 6d ago
Bausch issues update on Xifaxan patent dispute with Norwich
Healthcare Bausch issues update on Xifaxan patent dispute with Norwich. The company has 45 days from receipt of the notice to file a patent infringement suit against Norwich. Norwich has filed with the FDA to market a generic version of bausch’s xifaxan 550 mg tablets.
Seeking Alpha · 6d ago
More
About BHC
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Webull offers Bausch Health Companies Inc stock information, including NYSE: BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.